Effect of Abciximab Therapy in Patients Undergoing Coronary Angioplasty for Acute ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock.
Circ J
; 79(7): 1568-74, 2015.
Article
en En
| MEDLINE
| ID: mdl-25912694
ABSTRACT
BACKGROUND:
The effect of abciximab on survival in patients with ST-elevation myocardial infarction (STEMI) complicated by cardiogenic shock (CS) undergoing primary percutaneous coronary intervention (PCI) is not clear. METHODSâANDâRESULTS:
We evaluated outcome in 410 consecutive patients with STEMI and CS who underwent PCI treated without (n=123) or with (n=287) abciximab. The endpoint was survival at 1-year follow-up. The predictors of death at 1 year were also investigated. The groups with and without abciximab had similar survival at 1-year follow-up. Propensity score-adjusted Cox proportional hazards model identified age (adjusted hazard ratio [HR], 1.02; 95% confidence interval [95% CI] 1.01-1.03, P=0.001), oro-tracheal intubation (HR, 1.49; 95% CI 1.12-1.96, P=0.05), post-PCI TIMI flow grade 0-1 (HR, 2.08; 95% CI 1.52-2.83, P=0.0001) but not abciximab use (HR, 1.08; 95% CI 0.70-1.60, P=0.60) as independent predictors of death at 1-year follow-up. Cox adjusted 1-year survival rates were 42.8% and 51.6%, (P=0.56) in patients treated without vs. with abciximab, respectively.CONCLUSIONS:
Patients with STEMI complicated by CS undergoing PCI treated with or without abciximab have similar 1-year survival rates; age, final TIMI 0-1 and oro-tracheal intubation are predictors of death.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Choque Cardiogénico
/
Fragmentos Fab de Inmunoglobulinas
/
Angioplastia Coronaria con Balón
/
Anticuerpos Monoclonales
/
Infarto del Miocardio
Tipo de estudio:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2015
Tipo del documento:
Article